NGM BIOPHARMACEUTICALS INC (NGM)
US62921N1054 - Common Stock
ChartMill assigns a Buy % Consensus number of 49% to NGM. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.7. This target is 10.11% above the current price.
NGM was analyzed by 11 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about NGM.
In the last month the buy percentage fell by 26 points. So the trust of analysts is decreasing.
NGM was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-12 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2024-02-28 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-11-22 | B. Riley Securities | Maintains | Buy -> Buy |
| 2023-05-03 | Citigroup | Initiate | Buy |
| 2023-03-30 | B. Riley Securities | Maintains | Buy |
| 2022-11-04 | Raymond James | Maintains | Outperform |
| 2022-10-18 | Cowen & Co. | Maintains | Outperform |
| 2022-10-18 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2022-10-18 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-17 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-10-17 | Jefferies | Downgrade | Buy -> Hold |
| 2022-10-07 | B. Riley Securities | Maintains | Buy |
| 2022-07-20 | Jefferies | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2021-11-05 | Raymond James | Maintains | Strong Buy |
| 2021-09-17 | BMO Capital | Maintains | Outperform |
| 2021-09-13 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2021-08-06 | Raymond James | Maintains | Outperform |
| 2021-05-24 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2021-03-05 | Chardan Capital | Maintains | Buy |
| 2021-03-05 | Raymond James | Maintains | Strong Buy |